🏥

Abbott Acquires Exact Sciences

$23 Billion Cancer Diagnostics Deal Analysis

Deal Value

$23 billion (including debt)

Expected Close

Q2 2026

Premium

21.95%

Opportunity

$65-133M over 36 months

📋Deal Summary

AcquirerAbbott Laboratories

TargetExact Sciences Corporation

Equity Value$21 billion

Net Debt$1.8 billion

Price per Share$105 cash

Premium21.95%

AnnouncedNovember 20, 2025

Expected CloseQ2 2026

Exact Sciences Revenue (2025)

$3+ billion projected

Abbott Diagnostics (2024)

$9.34 billion (down 6.5% YoY)

Combined Diagnostics

$12+ billion annually

2026-$0.20 per share

2027-$0.16 per share

Double-digit earnings growth returns in 2027

Market Size (2025)

$150+ billion globally (projected 2025)

Growth Rate

7-9% CAGR through 2030

Aging global populationIncreased cancer screening awarenessShift to non-invasive testingPrecision medicine adoptionEarly detection focus

Guardant Health (blood-based cancer detection)

Grail (Illumina's MCED platform)

Natera (oncology and prenatal testing)

Foundation Medicine (Roche-owned genomic profiling)

Traditional lab diagnostics (Quest, LabCorp)